4-chloro-1-ethyl-3-methylimidazo<1,5-a>quinoxaline | 134485-95-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-chloro-1-ethyl-3-methylimidazo<1,5-a>quinoxaline
• 英文别名: 4-Chloro-1-ethyl-3-methylimidazo[1,5-a]quinoxaline
• CAS: 134485-95-3
• 化学式: C₁₃H₁₂ClN₃
• 分子量: 245.711
• InChiKey: RIPCBVBUMNGXNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-1-ethyl-3-methylimidazo<1,5-a>quinoxaline 在 氨 作用下， 以 异丙醇 为溶剂， 反应 48.0h， 以87%的产率得到1-ethyl-3-methylimidazo[1,5-a]quinoxalin-4-amine
  参考文献：
  名称：

  Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

  摘要：

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

  DOI：

  10.1021/jm00113a002
• 作为产物：
  描述：

  2-ethyl-4-methyl-1-(2-nitrophenyl)-1H-imidazole 在 palladium on activated charcoal 氢气 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 8.5h， 生成 4-chloro-1-ethyl-3-methylimidazo<1,5-a>quinoxaline
  参考文献：
  名称：

  Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

  摘要：

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

  DOI：

  10.1021/jm00113a002